Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Everest Approved to Launch Triple-Negative Breast Cancer ADC in Singapore

publication date: Feb 11, 2022

Shanghai Everest Medicines was approved to launch Trodelvy® (sacituzumab govitecan) in Singapore to treat triple-negative breast cancer. It is Edison's first marketing approval. Trodelvy, a TROP-2 antibody conjugate, is approved as a third-line treatment for adult patients with unresectable advanced or metastatic triple-negative breast cancer. In 2019, Everest acquired Greater China rights to Trodelvy from Immunomedics (now part of Gilead) in an agreement worth up to $835 million. Edison expects additional Trodelvy approvals from China and other southeast Asian countries later this year. More details....

Stock Symbol: (HK: 1952)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.